Skip to content

Halozyme Therapeutics HALO Ratios & Valuation

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Gross margin82.8%-0.8pp83.6%-0.9pp84.5%+0.3pp84.2%+0.8pp83.4%-0.9pp
Efficiency
Asset turnover0.6×0.0×0.6×0.0×0.6×0.0×0.6×0.0×0.5×0.0×
Liquidity
Current ratio2.8×-1.9×4.7×+3.1×1.6×-6.8×8.4×0.0×8.4×+0.6×
Leverage
Debt-to-equity9.9×-34.7×44.6×+41.5×3.1×-1.6×4.6×+1.4×3.2×-1.0×
Per Share
Book value per share$1.79+354%$0.39-90.4%$4.12+53.7%$2.68-29.6%$3.81+35.5%
Valuation
Market capitalization$7.66B-3.3%$7.91B-7.7%$8.58B+29.2%$6.64B-15.7%$7.88B+29.6%
Price / sales5.1×-0.6×5.7×-1.2×6.9×+1.3×5.6×-1.6×7.3×+1.3×
Price / book34.9×-127×162.1×+145×17×-2.9×20×+3.6×16.3×-0.4×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Halozyme Therapeutics's profit margins?
Halozyme Therapeutics (HALO) runs a 82.8% gross margin and a 59.3% operating margin, with a 47.9% net margin.
Where do Halozyme Therapeutics's ratios come from?
Every ratio is computed from Halozyme Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.